Lazard Asset Management LLC Has $3.10 Million Stake in Biogen Inc. $BIIB

Lazard Asset Management LLC reduced its position in shares of Biogen Inc. (NASDAQ:BIIB) by 63.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,935 shares of the biotechnology company’s stock after selling 29,188 shares during the quarter. Lazard Asset Management LLC’s holdings in Biogen were worth $3,105,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Rothschild Investment LLC increased its stake in shares of Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares during the last quarter. Meeder Advisory Services Inc. raised its holdings in shares of Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 57 shares during the period. Kera Capital Partners Inc. lifted its stake in Biogen by 3.5% in the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 58 shares during the last quarter. Parallel Advisors LLC lifted its stake in Biogen by 1.5% in the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after purchasing an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in Biogen by 24.4% during the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 66 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Down 2.4%

Shares of BIIB stock opened at $202.95 on Friday. Biogen Inc. has a 12-month low of $124.56 and a 12-month high of $219.72. The company has a market capitalization of $29.99 billion, a PE ratio of 35.92, a price-to-earnings-growth ratio of 6.28 and a beta of 0.16. The firm has a 50 day moving average price of $201.23 and a two-hundred day moving average price of $190.60. The company has a quick ratio of 2.41, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, analysts predict that Biogen Inc. will post 12.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BIIB shares. Citigroup boosted their price target on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. JPMorgan Chase & Co. raised their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Royal Bank Of Canada decreased their target price on Biogen from $242.00 to $240.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Wedbush increased their price target on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $223.36.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.